0001493152-24-005944.txt : 20240212
0001493152-24-005944.hdr.sgml : 20240212
20240212213012
ACCESSION NUMBER: 0001493152-24-005944
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240211
FILED AS OF DATE: 20240212
DATE AS OF CHANGE: 20240212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Samuel George A. III
CENTRAL INDEX KEY: 0001878732
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12830
FILM NUMBER: 24622330
MAIL ADDRESS:
STREET 1: C/O LINEAGE CELL THERAPEUTICS, INC.
STREET 2: 2173 SALK AVENUE, SUITE 200
CITY: CARLSBAD
STATE: CA
ZIP: 92008
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc.
CENTRAL INDEX KEY: 0000876343
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943127919
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2173 SALK AVENUE
STREET 2: SUITE 200
CITY: CARLSBAD
STATE: CA
ZIP: 92008
BUSINESS PHONE: 5105213390
MAIL ADDRESS:
STREET 1: 2173 SALK AVENUE
STREET 2: SUITE 200
CITY: CARLSBAD
STATE: CA
ZIP: 92008
FORMER COMPANY:
FORMER CONFORMED NAME: BIOTIME INC
DATE OF NAME CHANGE: 19930328
4
1
ownership.xml
X0508
4
2024-02-11
0
0000876343
Lineage Cell Therapeutics, Inc.
LCTX
0001878732
Samuel George A. III
2173 SALK AVENUE, SUITE 200
CARLSBAD
CA
92008
0
1
0
0
General Counsel/Secretary
0
Common Shares, no par value
2024-02-11
4
M
0
6076
A
9674
D
Common Shares, no par value
2024-02-11
4
F
0
2490
1.08
D
7184
D
Restricted Stock Units
0.00
2024-02-11
4
M
0
6076
0.00
D
Common Shares
6076
12151
D
Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options.
Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026.
/s/ George A. Samuel III
2024-02-12